NCT01100944 2017-08-10
A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated